Structure-Based Virtual Screening for Novel EGFR Tyrosine Kinase Inhibitors: An In Silico Study
DOI:
https://doi.org/10.5281/zenodo.22637926Keywords:
EGFR, tyrosine kinase inhibitor, virtual screening, molecular docking, drug resistanceAbstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase drives a substantial fraction of non-small-cell lung
cancers, and acquired resistance mutations such as T790M and C797S continue to limit the durability of approved inhibitors.
Objective: This review synthesises published structure-based virtual screening (SBVS) methodology and EGFR inhibitor discovery
literature rather than reporting a new screening campaign. Methods: We narratively surveyed peer-reviewed docking,
pharmacophore, and molecular dynamics studies targeting EGFR crystal structures. Findings: Reported studies consistently
identify druglike hits with favourable predicted binding and ADMET profiles against wild-type and mutant EGFR. Conclusions:
Consensus SBVS pipelines combining docking, dynamics, and free-energy refinement remain productive for prioritising EGFR TKI
candidates for resistance mutants.
References
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-181. doi:10.1038/nrc2088
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. doi:10.1056/NEJMoa040938
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. doi:10.1126/science.1099314
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792. doi:10.1056/NEJMoa044238 Table 2: Principal computational stages and representative tools recurring across cited EGFR structure-based virtual screening studies. Stage Representative Purpose Key tool(s) reference Library curation ZINC database Source of [15,16] purchasable, drug-like candidate compounds Pharmacophore Ligand-based Pre-filter libraries [19] filtering pharmacophore models by required hinge-binding features Molecular AutoDock Vina, Glide Rank candidate [17,18] docking poses in the EGFR ATP-binding site ADMET SwissADME Prioritise hits [20] prediction with drug-like pharmacokinetic profiles Dynamics / free Molecular dynamics; Refine pose [27] energy MM-PBSA/MM-GBSA stability and re-rank binding free energy
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334. doi:10.1200/JCO.2012.44.2806
Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64(18):6652-6659. doi:10.1158/0008-5472.CAN-04-1168
Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061. doi:10.1158/2159-8290.CD-14-0337
Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-1699. doi:10.1056/NEJMoa1411817
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-562. doi:10.1038/nm.3854
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935-949. doi:10.1038/nrd1549
Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14(16):1923-1938. doi:10.2174/1568026614666140929124445
Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265-46272. doi:10.1074/jbc.M207135200
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957. doi:10.1056/NEJMoa0810699
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132. doi:10.1056/NEJMoa050753
Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45(1):177-182. doi:10.1021/ci049714+
Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012;52(7):1757-1768. doi:10.1021/ci3001277
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi:10.1002/jcc.21334
Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-1749. doi:10.1021/jm0306430
Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010;15(11-12):444-450. doi:10.1016/j.drudis.2010.03.013
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:10.1038/srep42717
Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: a comprehensive drug discovery study using commercial databases. PLoS One. 2024;19(11):e0311527. doi:10.1371/journal.pone.0311527
Identification of new EGFR inhibitors by structure-based virtual screening and biological evaluation. Int J Mol Sci. 2024;25(3):1887. doi:10.3390/ijms25031887
Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies. J Biomol Struct Dyn. 2024;42(19):9834-9848. doi:10.1080/07391102.2023.2256887
In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation. J Biomol Struct Dyn. 2021;39(4):1225-1238. doi:10.1080/07391102.2020.1734092
Discovery of novel small molecule EGFR inhibitory leads by structure and ligand-based virtual screening. Med Chem Res. 2016;25(11):2478-2489. doi:10.1007/s00044-016-1728-2
Statistical analysis of EGFR structures' performance in virtual screening. J Comput Aided Mol Des. 2015;29(11):1071-1080. doi:10.1007/s10822-015-9877-9
Wang E, Sun H, Wang J, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 2019;119(16):9478-9508. doi:10.1021/acs.chemrev.9b00055
